Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
The Effct of Chitooligosaccharide on Immune Function in Healthy Adults
This study has been completed.
Sponsored by: Eulji University Hospital
Information provided by: Eulji University Hospital
ClinicalTrials.gov Identifier: NCT00468962
  Purpose

Functional properties of chitooligosaccharides have been studied for antitumor activity, immunostimulating effects, antimicrobial activity, free radical scavening activity, adn angiotensin I converting enzyme inhibitory activity. Recent in vitro, and in vivo toxicity and absorbability studies have demonstrated that chitooligosaccharides have high absorbability and are essentially non-toxic. In the present study, we prepared a chitooligosaccharide with high absorbability and evaluated its effects on activation of immune function and cardiovascular funciton(lipid, atrial stiffness, etc) in healthy adults.

This study was a 8-week, randomized, double-blind clinical trial. The 30 volunteers were divided into a control group(n=10), half dose chitooligosaccaride(FACOSTM) intake group(n=10), and full dose FACOS intake group(n=10). Peripheral blood mononuclear cells(PBMCs) were isolated and cultured in 12 well plate for 48 hours. Cytokine production by PBMCs pre- and postintervention were measured simultaneously after stimulation with lipopolysaccaride.


Condition Intervention Phase
Immunity
Drug: FACOS (functional food)
Phase IV

U.S. FDA Resources
Study Type: Interventional
Study Design: Randomized, Double-Blind, Placebo Control, Parallel Assignment
  Eligibility

Ages Eligible for Study:   20 Years to 50 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • healthy adults(the ages between 20~50 year)

Exclusion Criteria:

  • food allergy and allergy skin disease
  • severe liver and kidney disease
  • pregnant, lactating women
  • cancer, stroke, etc.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00468962

Sponsors and Collaborators
Eulji University Hospital
Investigators
Principal Investigator: Hee-Jeong Choi, MD, Ph.D Eulji University Hospital
  More Information

Study ID Numbers: 07-05
Study First Received: May 2, 2007
Last Updated: May 2, 2007
ClinicalTrials.gov Identifier: NCT00468962  
Health Authority: Korea: Food and Drug Administration

Study placed in the following topic categories:
Healthy

ClinicalTrials.gov processed this record on January 16, 2009